<DOC>
	<DOC>NCT00271271</DOC>
	<brief_summary>Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the combination</brief_summary>
	<brief_title>Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Nonsmall cell bronchopulmonary cancer established by histological and/or cytological methods; Advanced or metastatic disease (stage IIIB or IV); At least one measurable lesion with one dimension (&gt;= 20 mm by CT scan or &gt;=10 mm by CT scan) outside of the irradiated area; No prior chemotherapy; Previous radiotherapy permitted as long as there has been a washout period of at least 4 weeks; Age &gt;= 18 years old; ECOG Performance Status (PS): 01; Life expectancy &gt;3 months; Hepatic and renal functions and blood count satisfactory: Blood counts: white blood cells &gt;= 3.0 x 10^9/l, neutrophils &gt;= 1.5 x 10^9/l, platelets &gt;= 150 x 10^9/l, haemoglobin &gt;= 9 g/dl, Hepatic function: bilirubin within the limit of the normal upper value, aspartate transaminases (AST) or alanine transaminases (ALT) &lt;= 2.5 times the normal upper value Renal function: creatinine clearance (calculated according to Cockroft and Gault) &gt;= 40 ml/min; Patients of reproductive age must use an effective contraceptive method; Informed consent form signed before any procedure undertaken connected with the study Pregnant or breastfeeding patient; Past record of other cancers (excluding basocellular or epidermoid cutaneous carcinoma or cured carcinoma of the cervix); Symptomatic cerebral or leptomeningeal metastases; Symptomatic peripheral neuropathy &gt; 1 (NCICTC grade); Presence of a serious disease or medical condition incompatible with the study (at the discretion of the investigator); Treatment with another test product or participation in another therapeutic trial in the 4 weeks preceding inclusion in the study; Concomitant treatment by any other anticancer therapy; Concomitant treatment with phenytoin. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>